Xeris files $75M IPO to fund shelf-stable glucagon rescue injector

Diabetes blood sugar testing
Xeris aims to file an NDA this year for the first room temperature-stable glucagon rescue injection, for diabetes patients with severe hypoglycemia. (Pixabay)

Xeris Pharmaceuticals plans to go public, filing for a $75 million IPO on the Nasdaq, according to the firm Renaissance Capital. No pricing terms have yet been disclosed.

The Chicago-based company is developing a handheld glucagon rescue pen for severe hypoglycemia, dubbed the G-Pen, as well as a bi-hormonal, closed-loop artificial pancreas. The pen is currently in a phase 3b trial, according to Xeris. Other glucagon-based products for hypoglycemia and hyperinsulinism are undergoing phase 2 studies.

In February, the company completed two phase 3 clinical trials and a human factors study of the rescue pen device. A phase 3b trial was then launched to evaluate the entire treatment episode compared to current emergency glucagon, including preparation and administration times.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“We believe our glucagon autoinjector has the potential to offer benefits over currently marketed glucagon kits that require reconstitution and syringe filling prior to administration in a life-threatening emergency setting,” CEO Paul Edick said. Xeris’ formulation aims to provide the first soluble, room-temperature stable, ready-to-inject glucagon.

Founded in 2005, Xeris plans to trade using the stock symbol XERS. The company raised $55 million earlier this year, with $10 million through series C investments and $45 million in a loan agreement.

The proceeds will fund the auto-injector’s NDA submission planned for the second quarter of this year, according to Edick. A previous series C round in May 2017 raised another $30 million, and was used to support late-phase development.

Suggested Articles

Medtronic has received FDA approval for a drug-coated balloon designed to clear the access points used by patients undergoing dialysis treatments.

J&J's DePuy Synthes division has launched a new fixation system to expand treatment options for patients with frail bones in the neck and upper back.

Tokyo-based Heartseed has raised 2.8 billion yen, or about $26 million U.S., to help develop its stem cell-based treatment for heart failure.